Programmed death protein 1 (PD1) is a common immunosuppressive member on the
surface of T cells and plays an imperative part in downregulating the immune system and …

Triple negative breast cancer (TNBC) is a subtype of breast tumor lacking hormone
receptors expression and HER2 gene amplification and represents 24% of newly diagnosed …

Triple-negative breast cancer (TNBC) is a rare cancer, characterized by high metastatic
potential and poor prognosis, and has limited treatment options. The current standard of …

Background Increasing studies have shown that circRNA is closely related to the
carcinogenesis and development of many cancers. However, biological functions and the …

Abstract N6-methyladenosine (m6A) serves as the most common and conserved internal
transcriptional modification. However, the roles of m6A on cervical cancer (CC) …

The functional status of innate immune cells is a considerable determinant of effective
antitumor immune response. However, the triple-negative breast cancer tumor …

Breast cancer is the most prevalent cancer in women worldwide. Triple‑negative breast
cancer (TNBC) is characterized by the lack of expression of estrogen receptor, progesterone …

Targeting of estrogen receptor is commonly used as a first-line treatment for hormone-
positive breast cancer patients, and is considered as a keystone of systemic cancer therapy …

Triple negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC) are amongst
the most aggressive forms of solid tumors. TNBC is highlighted by absence of genetic …

Triple‐negative breast cancer (TNBC) is still the most aggressive cancer in women.
Combination chemotherapy holds great potential for cancer therapy; however, the off‐target …